Literature DB >> 12672028

Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma.

Muthusamy Viswanathan1, Nobuo Tsuchida, Govindaswamy Shanmugam.   

Abstract

Aberrant promoter hypermethylation of tumor-associated genes leading to their inactivation is a common event in many cancer types. Using a sensitive restriction-multiplex PCR method, we studied the promoter hypermethylation profile of the p16, p15, hMLH1, MGMT and E-cad genes in oral squamous cell carcinoma (OSCC) of Indians. We analyzed a total of 51 samples for the p15 tumor-suppressor gene and 99 samples for each of the remaining genes. Our studies indicate an incidence of promoter hypermethylation of 23% each for p16 and p15, 8% for hMLH1, 41% for MGMT and 35% for E-cad. We observed aberrant hypermethylation of the promoter region of at least 1 of these genes in 74.5% of cases (n = 51) for which all the 5 genes were studied. Abnormal methylation was detected in tumors irrespective of stage and location in the oral cavity, whereas no abnormal methylation was detectable in normal oral squamous tissues obtained from 25 OSCC patients. Detection of aberrant hypermethylation patterns of cancer-associated genes listed above is therefore suitable for diagnosis of OSCC in individuals at high risk for this disease. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672028     DOI: 10.1002/ijc.11028

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Pattern of nonspecific (or global) DNA methylation in oral carcinogenesis.

Authors:  Chandrika J Piyathilake; Walter C Bell; Jennifer Jones; Olga L Henao; Douglas C Heimburger; Alain Niveleau; William E Grizzle
Journal:  Head Neck       Date:  2005-12       Impact factor: 3.147

2.  Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa.

Authors:  Keizo Kato; Akira Hara; Toshiya Kuno; Hideki Mori; Tomomi Yamashita; Makoto Toida; Toshiyuki Shibata
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

3.  Promoter hypermethylation in Indian primary oral squamous cell carcinoma.

Authors:  Jatinder Kaur; Semra Demokan; Satyendra Chandra Tripathi; Muzafar Ahmad Macha; Shahnaz Begum; Joseph A Califano; Ranju Ralhan
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

4.  DNA methylation biomarkers for head and neck squamous cell carcinoma.

Authors:  Chongchang Zhou; Meng Ye; Shumin Ni; Qun Li; Dong Ye; Jinyun Li; Zhisen Shen; Hongxia Deng
Journal:  Epigenetics       Date:  2018-08-10       Impact factor: 4.528

Review 5.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

6.  Molecular characterization of head and neck cancer: how close to personalized targeted therapy?

Authors:  Maria J Worsham; Haythem Ali; Jadranka Dragovic; Vanessa P Schweitzer
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

Review 7.  Delineating an epigenetic continuum in head and neck cancer.

Authors:  Maria J Worsham; Josena K Stephen; Kang Mei Chen; Shaleta Havard; Veena Shah; Glendon Gardner; Vanessa G Schweitzer
Journal:  Cancer Lett       Date:  2012-03-01       Impact factor: 8.679

8.  Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.

Authors:  Daniel Weiss; Christian Stockmann; Katrin Schrödter; Claudia Rudack
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

Review 9.  Epigenetics: connecting environment and genotype to phenotype and disease.

Authors:  S P Barros; S Offenbacher
Journal:  J Dent Res       Date:  2009-05       Impact factor: 6.116

10.  Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation.

Authors:  Emanuela Taioli; Camille Ragin; Xiao-Hong Wang; Jiangying Chen; Scott M Langevin; Ashley R Brown; Susanne M Gollin; Seymour Garte; Robert W Sobol
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.